Follow-up after surgery for liver metastases: the FUTURE-mets study
- Conditions
- Colorectal cancerColorectal liver metastasesQuality of lifeShared decision makingFollow-upCost-effectiveness
- Registration Number
- NL-OMON26930
- Lead Sponsor
- Prof. Dr. C. Verhoef, Erasmus MC Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 138
•Patients with CRLM treated with curative intent
•Age = 18 years
•ECOG performance status = 2 (Appendix A)
•Histologically confirmed and previously resected primary colorectal carcinoma
•Disease-free at three to six months after CRLM treatment (assessed by medical imaging)
•Metastatic extrahepatic disease (EHD) precluding curative treatment of CRLM
•Patients with confirmed hereditary CRC
•Patients enrolled in other studies that require strict adherence to any specific follow-up practice with regular imaging – yearly or more frequent – of the abdomen and/or thorax
•Patients with comorbidity that requires imaging of the abdomen and/or thorax every year or more frequent
•Inability to complete the questionnaires due to illiteracy and/or insufficient proficiency of the Dutch language
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of this study is the quality of life. The effect of follow-up on quality of life will be assessed by the validated European Organisation for Research and Treatment of Cancer core quality of life questionnaire – Emotional Functioning Scale (EORTC QLQ-C30).
- Secondary Outcome Measures
Name Time Method